Both of these gene editing stocks have a lot going for them, but which one is better?
News & Analysis: Sangamo Therapeutics
The gene editing company published a proof-of-concept for "smart" immunotherapies. The idea may catch on.
Investors didn't like the preliminary results from an early-stage study.
These gene-editing trailblazers continue advancing exciting new approaches to treating inherited diseases.
SGMO earnings call for the period ending September 30, 2019.
The gene-editing sector has a bright future ahead, but does that make every company in that market a buy?
SGMO earnings call for the period ending June 30, 2019.
Pipeline progress was the big story in Q2 for this clinical-stage biotech.
The biotech's gene therapy to treat hemophilia A looks promising.
Sangamo Therapeutics reported positive data on its gene therapy for hemophilia, and CannTrust Holdings received a noncompliance report from Canadian authorities.